Supplementary Data from The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Autor: Ruslan D. Novosiadly, Michael Kalos, Gerald E. Hall, David Surguladze, Gregory P. Donoho, Thompson N. Doman, Jason R. Manro, Frank C. Dorsey, Krishna Chodavarapu, Manisha Brahmachary, Bo Tan, Alexander Nikolayev, Kenneth D. Roth, Carmine Carpenito, Shuang Luo, Xiaodong Huang, Bonita D. Jones, Catalina M. Meyer, Yanxia Li, Andrew Capen, Darin Chin, Andreas Sonyi, Erik R. Rasmussen, Zhao Hai Lu, Nelusha Amaladas, Sandaruwan Geeganage, David A. Schaer

Figure S1. Efficacy of pemetrexed in Lewis Lung carcinoma model and metabolomic analysis of MC38 tumor bearing mice treated with 50 mg/kg of pemetrexed Figure S2. T cell inflamed phenotype induced by pemetrexed is modestly reduced in tumors upon comb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dcf5c80af2bf8dacf087ab7a6132752
https://doi.org/10.1158/1078-0432.22471421

Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens

Autor: Jordan J. Feld, Manon Ragonnet-Cronin, Michelle Miller, John McNally, Neeru Bhardwaj, Krishna Chodavarapu, Ross Martin, Evguenia S. Svarovskaia, Alessandra Mangia, Joel O. Wertheim, A. Osinusi, Mark S. Sulkowski, Ben Murrell, Diana M. Brainard, Hongmei Mo, Silvia Chang

Publikováno v: Journal of Viral Hepatitis. 25:344-353

Treatment with the direct-acting antiviral agent (DAA) sofosbuvir (SOF), an NS5B inhibitor, and velpatasvir (VEL), an NS5A inhibitor, demonstrates viral cure rates of ≥95% in hepatitis C virus (HCV) genotypes (GT) 1-6. Here, we investigated intrapa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33b85383074360b7e4a49e92950dc541
https://doi.org/10.1111/jvh.12825

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Autor: Yanxia Li, Frank C. Dorsey, Jason Manro, Kenneth D. Roth, Erik R. Rasmussen, Ruslan D. Novosiadly, Gerald Hall, Andrew Capen, Bonita D. Jones, Zhao Hai Lu, Bo Tan, Gregory P. Donoho, Darin Chin, Manisha Brahmachary, David Schaer, Thompson N. Doman, Sandaruwan Geeganage, Catalina Meyer, Nelusha Amaladas, Andreas Sonyi, Michael Kalos, Carmine Carpenito, Krishna Chodavarapu, Shuang Luo, Xiaodong Huang, David Surguladze, Alexander Nikolayev

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 25(23)

Purpose: Combination strategies leveraging chemotherapeutic agents and immunotherapy have held the promise as a method to improve benefit for patients with cancer. However, most chemotherapies have detrimental effects on immune homeostasis and differ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4d28af80d9d6edb3d4c795aee1aeedc
https://pubmed.ncbi.nlm.nih.gov/31562205

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

Autor: Frank C. Dorsey, Thompson N. Doman, Kenneth D. Roth, Yanxia Li, Ruslan D. Novosiadly, Gerald Hall, Greg Donoho, Carmine Carpenito, Jason Manro, David Schaer, Erik R. Rasmussen, David Surguladze, Xiaodong Hong, Bonita D. Jones, Bo Tan, Alexander Nikolayev, Krishna Chodavarapu, Zhao Hai Lu, Shuang Luo, Manisha Brahmachary, Andrew Capen, Andreas Sonyi, Michael Kalos, Nelusha Amaladas, Darin Chin, Sandaruwan Geeganage, Catalina Meyer

Publikováno v: Cancer Research. 79:3945-3945

Combination strategies leveraging chemotherapy and immunotherapy have held the promise as a method to improve benefit to cancer patients. However, most chemotherapies have detrimental effects on immune homeostasis and do not induce immunogenic cell d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2bbe0a693be054d24e0d0e7de2340a9e
https://doi.org/10.1158/1538-7445.am2019-3945

Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses

Autor: Diana M. Brainard, Krishna Chodavarapu, John McNally, Kosh Agarwal, Tania M. Welzel, Evguenia S. Svarovskaia, Neeru Bhardwaj, Stefan Zeuzem, Hongmei Mo, Gregory Camus, Michael D. Miller, Charlotte Hedskog, Ira M. Jacobson

Publikováno v: Welzel, T, Bhardwaj, N, Hedskog, C, Chodavarapu, K, Camus, G, McNally, J, Brainard, D, Miller, M D, Mo, H, Svarovskaia, E, Jacobson, I, Zeuzem, S & Agarwal, K 2017, ' Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses ', Journal of Hepatology . https://doi.org/10.1016/j.jhep.2017.03.014

Background & Aims HCV genotype, subtype, and presence of resistance-associated substitutions (RASs) are key determinants for the selection of direct-acting antiviral (DAA) treatment regimens. However, current HCV genotyping assays have limitations in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a62fd0a01accdc9027bb5d325420d24
https://pubmed.ncbi.nlm.nih.gov/28343981